60 Degrees Pharmaceuticals (SCTP) Investor presentation summary

Strategic focus and mission

• Focused on developing and commercializing products for unmet medical needs in vector-borne diseases, especially malaria and babesiosis.

• Mission centers on addressing significant gaps in prevention and treatment for these diseases.

Product portfolio and pipeline

• ARAKODA (tafenoquine) is FDA-approved for malaria prophylaxis, with commercial launch in 2019 and robust US distribution.

• ARAKODA is the only prophylactic therapy protecting against all malaria stages, with no drug resistance and convenient weekly dosing.

• Pipeline includes expansion into babesiosis treatment, with orphan drug status and multiple ongoing clinical trials.

• Additional products for tick-borne diseases and veterinary indications are in development.

Market opportunity and commercial strategy

• US malaria prevention market estimated at $50-70M, with growing commercial revenues and profitability targeted for 2028.

• Maximum addressable market through 2035: 450,000 malaria and 350,000 babesiosis patients.

• Commercial strategy includes increasing awareness, differentiating ARAKODA, and expanding access via partnerships and eCommerce.

• Sales growth achieved with lean investment, despite temporary stock-out in 2025.